Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The 6th Annual Oncology Student Symposium was held at St Anne’s College, for the second time, on Monday, 9 July.

© Luana Campos Soares
Prize cover image: “In vivo brain electroporation of nuclear GFP and cytoplasmic tdTomato showed migration of neural stem cells from the subventricular zone following differentiation into glial cells (oligodendrocytes/astrocytes)” - Luana Campos Soares.

The day went really well, and the only complaint about the weather was that it was a bit stuffy in the marquee! Second year students gave their talks in the - thankfully air-conditioned - Mary Ogilvie lecture theatre; and first years presented their posters in the marquee on the lawn in St Anne's Quad. The standard was again agreed to be very high, with clear and confident talks and eye-catching posters which were eloquently explained.


The prizes for the four categories were awarded as follows:

The front cover Image Prize went to Luana Campos Soares (Eric O'Neill and Francis Szele Group) - for the second year running - with "The OLIG-ator" (It was judged blind, so this was complete chance!)

The First Year Poster Presentation Prize went to Richard Baugh (Len Seymour Group) with "Enhancing glioblastoma oncolytic virotherapy with locally delivered macrophage activators" Runners up were Linda van Bijsterveldt (Tim Humphrey and Kate Vallis Group) and Rosalin Cooper (Ben Fairfax and Mark Middleton Group).

The Second Year Oral Presentation Prize was won by Sam Hume (Grigory Dianov and Kristijan Ramadan Group) with "NUCKS nurtures neoplasms". Second place was Timo Reisländer (Madalena Tarsounas Group) and joint third place went to Sally Frost (Len Seymour group and Tzveta Pokrovska (Len Seymour Group).

Best Question Prize during the oral presentations went to Egon Jacobus (Len Seymour Group).

Congratulations to all the prize winners.

Similar stories

Machine Learning Predicts SETD2 Mutation Status with Unprecedented Accuracy using DNA methylation

In a pan-cancer analysis spanning 24 different cancer type, researchers shed light on the critical role of SETD2 in tumourigenesis.

Oxford to launch UK’s first trials unit dedicated to conducting precision prevention and early detection studies

Oxford researchers have been given a £1 million boost to support their strategy of developing cancer prevention treatments and early diagnostic tools for people at high risk of cancer.

Multi-cancer blood test shows real promise in NHS trial

An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those cases.

The Howat Foundation to fund Chair in Clinical Oncology

Oxford Cancer announce the endowment of a Chair in Clinical Oncology, thanks to generous philanthropic support from The Howat Foundation

New Oxford and Nottingham developed tool uses existing health records to predict people’s risk of developing lung cancer within the next 10 years

A team of researchers from the University of Oxford and the University of Nottingham have developed a new tool, called ‘CanPredict’, aimed at identifying the people most at risk of developing lung cancer over the next 10 years, and put them forward for screening tests earlier, saving time, money and, most importantly, lives.

Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment

New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.